Imipenem/ @entity9234 (IPM/CS) was administered to a total of 67 @entity1 with severe @entity281 complicating @entity1503 and @entity5 . Fifty @entity1 are included in the present analysis of efficacy and 64 in that of safety. 1. Out of 31 @entity1 with @entity1503 , responses were excellent in 10 @entity1 , good in 10 @entity1 , and the efficacy rate was 64.5%. Out of 19 @entity1 with @entity5 , responses were excellent in 8 @entity1 , good in 8 @entity1 and the efficacy rate was 84.2%. 2. For @entity1 whose responses to other antibiotics had been poor, the efficacy rate was 59.3% in the group with @entity1503 and 62.5% in the group with @entity5 . 3. The relationship between the neutrophil count and efficacy was studied in the @entity1 with @entity1503 . The efficacy rate for 8 @entity1 whose neutrophil counts were 500/mm3 or less was 75.0%. 4. For the @entity1 with @entity1503 , the efficacy rate for @entity1 from whom causative organisms were isolated was 70.0% and that for @entity1 for whom they were unknown was 61.9%. 5. Adverse reactions were observed in 3 @entity1 and abnormal laboratory test results in 2 @entity1 . However, they were mild and disappeared after discontinuation of this drug. From these results, IPM/CS is considered to be a useful antibiotic for the treatment of severe @entity281 complicating @entity1503 and @entity5 .

[Clinical evaluation of imipenem/ @entity9234 against severe XXXX complicating @entity1503 and @entity5 ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['solid tumors'] @entity9234 :: ('MESH:D015377', 'Chemical') :: ['cilastatin sodium'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological disorders'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']
@entity281 :: (MESH:D007239,Disease) :: ['infections']
